Acelyrin Announced That Data From Its Phase 1/2 Clinical Trial Of Lonigutamab In Thyroid Eye Disease Will Be Shared At The Annual Meeting Of The European Society Of Ophthalmic Plastic And Reconstructive Surgery
Acelyrin Announced That Data From Its Phase 1/2 Clinical Trial Of Lonigutamab In Thyroid Eye Disease Will Be Shared At The Annual Meeting Of The European Society Of Ophthalmic Plastic And Reconstructive Surgery
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.